⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
QURE News
uniQure N.V.
Form 8-K
sec.gov
QURE
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
globenewswire.com
QURE
AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
globenewswire.com
SNY
MRK
BMY
AZN
AMGN
PFE
GENK
QURE
ABSI
NVDA
Global Huntington's Disease Treatment Market 2026-2031 - Advancements in Novel Therapeutics to Drive Growth
globenewswire.com
PFE
TEVA
NBIX
ALNY
IONS
NVS
QURE
SANG
PTC
WVE
Form 8-K
sec.gov
QURE
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
globenewswire.com
QURE
uniQure to Announce Second Quarter 2026 Financial Results
globenewswire.com
QURE
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
globenewswire.com
QURE
Form 8-K
sec.gov
QURE
uniQure Announces Pricing of Upsized $225 Million Public Offering
globenewswire.com
QURE